Home' Australian Pharmacist : Australian Pharmacist October 2014 Contents Australian Pharmacist October 2014 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Airsense 10 AutoSet for Her
The first sleep therapy solution tailored
to the unique needs of women with
obstructive sleep apnoea (OSA) is now
available in Australia. ResMed is urging
doctors to have the sleep health of
their female patients top of mind given
women are commonly underdiagnosed
with OSA, increasing their risk of
diabetes and cardiovascular death.
The company says that sleep apnoea,
usually viewed as an older man’s
condition, is more prevalent in women
than previously acknowledged.
Professor David Hillman, Chair, Sleep
Health Foundation and Director of
the West Australian Sleep Disorders
Research Institute in Perth said: ‘It is
important that physicians are accurately
diagnosing sleep apnoea in women. We
need to appreciate that women present
to clinics with non-classical symptoms
rather than the classic signs expressed
by men, such as snoring.’
The Airsense 10 AutoSet for Her therapy
device uses the first-ever dedicated
algorithm tailored to respond to
female-specific characteristics of sleep
disordered breathing and is based on
RedMed’s proven AutoSet algorithm and
delivers therapeutic responses that have
been tailored to the characteristics of
OSA in women. Typically, women with
sleep apnoea take longer to fall asleep,
have more flow limitations (reuction
in volume of air going into the lungs),
and more frequent sleep arousals than
men. Women also tend to have a lower
apnea-hypopnea index (AHI), and fewer
and shorter apnoeas than men, with a
greater proportion of apnoeas occurring
during rapid eye movement (REM) sleep.
Flordis has developed an Ask/Assess/
Advise Protocol to assist pharmacy
staff to engage with their customers
about their sinus health. The protocol
provides guidance on questions to ask
customers to help determine appropriate
recommendations for treatment.
In particular it helps assess if customers are
experiencing sinusitis as a consequence
of allergic rhinitis and whether a Sinupret
Forte recommendation may be suitable.
Pharmacy patients suffering from
allergic rhinitis are more likely to
develop sinusitis, as blocked sinuses
provide an ideal breeding ground
for bacteria and viruses leading to
Sinupret Forte is designed to provide
non-drowsy relief from sinusitis and
sinus pain. Its formulation of five herbs
has been used worldwide for more
than 70 years and, with over 30 years of
clinical research, its effectiveness has
been extensively researched. According
to Flordis, scientific research has shown
that Sinupret Forte has a three-way
action that unblocks sinuses by
improving drainage, reducing swelling
and congestion and relieves sinus pain
by reducing inflammation in the sinuses.
It may be used in conjunction with
antibiotics and decongestant therapy
as it has demonstrated a benefit when
used together with these medications.
Links Archive Australian Pharmacist September 2014 Australian Pharmacist November 2014 Navigation Previous Page Next Page